Chantal Mathieu
Expertise in
14
conditions

Chantal Mathieu

Leuven, VLG, BE 
Expertise in
14
conditions
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Chantal Mathieu practices in Leuven, Belgium. Ms. Mathieu is highly rated in 14 conditions, according to our data. Her top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), Islet Cell Transplantation, and Gastric Bypass.

Her clinical research consists of co-authoring 508 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Leuven, VLG, Belgium
Other Locations
Belgium
Rue De Bruxelles, 61, Namur, WAL 5000, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drug: Verapamil SR
Study Phase: Phase 2
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Biological, Drug
Study Drugs: AG019 - Low Dose, Teplizumab, AG019 - High Dose, AG019 - Low or High Dose
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

508 Total Publications

The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.
The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.
Journal: Journal of diabetes science and technology
Published: May 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mathieu's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile